Saniona has announced that Cephagenix, a joint venture with Professor Jes Olesen at the University of Copenhagen, has successfully raised up to 9 MEUR in tranched seed financing. The funding round was led by AdBio Partners and AbbVie Ventures and aims to accelerate the development of Cephagenix’s vascular KATP channel inhibitor …
BioStock: Saniona-backed Cephagenix secures 9 MEUR in seed financing
Saniona has announced that Cephagenix, a joint venture with Professor Jes Olesen at the University of Copenhagen, has successfully raised up to 9 MEUR in tranched seed financing. The funding round was led by AdBio Partners and AbbVie Ventures and aims to accelerate the development of Cephagenix’s vascular KATP channel inhibitor program, targeting novel anti-migraine therapies. BioStock reached out to Saniona’s CEO Thomas Feldthus for a comment.
Read the interview with Thomas Feldthus at biostock.se:
https://www.biostock.se/en/2025/01/saniona-backed-cephagenix-secures-9-meur-in-seed-financing/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
